These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4465915)

  • 1. [Platelet aggregation activity. Inhibitory effects of an alpha-blocking agent: nicergoline].
    Migne J; Saint-Maurice JP; Santonja R; Kunz S
    Sem Hop Ther; 1974 Dec; 50(10):649-55. PubMed ID: 4465915
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nicergoline and platelet aggregation. A review of experimental and clinical studies (author's transl)].
    Praga C; Tantalo V; Marangoni R
    Arzneimittelforschung; 1979; 29(8a):1270-6. PubMed ID: 540070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ultrastructural study on the effect of an inhibitor of platelet aggregation (author's transl)].
    Le Menn R; Migne J; Probst-Dvojakovic RJ
    Arzneimittelforschung; 1979; 29(8a):1278-82. PubMed ID: 540072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human platelet aggregation by oral administration of nicergoline. A double-blind study.
    Pogliani E; Volpe AD; Ferrari R; Recalcati P; Praga C
    Farmaco Prat; 1975 Dec; 30(12):630-40. PubMed ID: 1107066
    [No Abstract]   [Full Text] [Related]  

  • 5. [Ultrastructural study of the action of a blood platelet anti-aggregant. Application to nicergoline].
    Le Menn R; Migne J; Prost-Dvojakovic RJ
    Therapie; 1977; 32(2):205-14. PubMed ID: 898128
    [No Abstract]   [Full Text] [Related]  

  • 6. Nicergoline, an anti-aggregating agent which inhibits release of arachidonic acid from human platelet phospholipids.
    Lagarde M; Guichardant M; Ghazi I; Dechavanne M
    Prostaglandins; 1980 Apr; 19(4):551-7. PubMed ID: 7384555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A review of pharmacological studies on nicergoline].
    Moretti A; Arcari G; Pegrassi L
    Arzneimittelforschung; 1979; 29(8a):1223-7. PubMed ID: 44197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-mediated thrombosis in stenosed canine coronary arteries: inhibition by nicergoline, a platelet-active alpha-adrenergic antagonist.
    Bolli R; Ware JA; Brandon TA; Weilbaecher DG; Mace ML
    J Am Coll Cardiol; 1984 Jun; 3(6):1417-26. PubMed ID: 6715702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relaxing effect of nicergoline on the female urethra in peripheral neurogenic vesicosphincter dysfunctions].
    Galas JM; Grillot MJ; Vasse MG; Vaillandet M; Guillemin P
    J Urol (Paris); 1984; 90(8-9):563-5. PubMed ID: 6398829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Action of nicergoline on the cerebral circulatory insufficiency due to arteriosclerosis. Clinical and angioserographic evaluation].
    Bernini FP; Muras I; Maglione F; Smaltino F
    Farmaco Prat; 1977 Jan; 32(1):32-46. PubMed ID: 838039
    [No Abstract]   [Full Text] [Related]  

  • 11. Potentiation by an alpha-adrenolytic agent, nicergoline, of the cardiac effects of propranolol.
    Boismare F; Moore N; Decourt S; Paux G; Saligaut C; Chretien P
    Methods Find Exp Clin Pharmacol; 1983; 5(2):83-8. PubMed ID: 6876944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental study of nicergoline antianoxic activity (author's transl)].
    Truchaud M; Moriniere A
    Ann Pharm Fr; 1980; 38(1):35-42. PubMed ID: 7396338
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interaction between anti-aggregating and anticoagulant agents. A double blind study on the concomitant administration of nicergoline and acenocoumarols].
    Pogliani E; Recalcati P; Tantalo V; Bregnani P
    Arzneimittelforschung; 1979; 29(8a):1266-9. PubMed ID: 395954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of nicergoline in the prevention of postoperative thrombophlebitis].
    Kauffmann JP; Keller D; Calderoli H; Ackermann E; Hollender LF
    Med Chir Dig; 1981; 10(2):169-72. PubMed ID: 7230952
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hemodynamic study of nicergoline].
    Pony JC; Bourdonnec C; Amelot J; Dallerac J; Daubert JC; Gouffault J
    Ann Cardiol Angeiol (Paris); 1982; 31(1):67-70. PubMed ID: 7065627
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of nicergoline on cerebral blood flow (author's transl)].
    Iliff LD; Du Boulay GH; Marshall J; Ross Russell RW; Symon L
    Arzneimittelforschung; 1979; 29(8a):1277-8. PubMed ID: 540071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an alpha-blocking agent, nicergoline, on the interaction between blood platelets, elastin and endothelial cells.
    Rafelson ME; Migne J; Santonja R; Derouette JC; Robert L
    Biochem Pharmacol; 1980 Mar; 29(6):943-7. PubMed ID: 7387709
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of nicergoline on left ventricular function indexes. Comparative study in normotensive and hypertensive patients].
    Monassier JP; Coulbois PM; Weiss JB; Touhami L; Schaaf R; Jehl L; Klenklen F; Monassier C
    Ann Cardiol Angeiol (Paris); 1982; 31(2):155-60. PubMed ID: 7103399
    [No Abstract]   [Full Text] [Related]  

  • 19. Usefulness of an alpha-adrenergic blocking agent (nicergoline) in the treatment of diabetic angiopathy of lower limbs.
    Calvagno M
    Farmaco Prat; 1982 Jun; 37(6):200-5. PubMed ID: 7106277
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergic effect of prostacyclin (PGI2) and alpha-blocking-agent on adrenalin-induced human platelet aggregation.
    Pogliani E; Fantasia R; Colombi M; Praga C
    Thromb Haemost; 1980 Oct; 44(2):106. PubMed ID: 6109380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.